Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1Lymphoid 1Head & Neck 1Genitourinary 1CNS 1Breast 1

Conditions

Breast Neoplasms 17Prostatic Neoplasms 4Neoplasm Metastasis 4Melanoma 3Lung Neoplasms 3Colorectal Neoplasms 3Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Stomach Neoplasms 2Sarcoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Lymphoma 2Liver Neoplasms 2Kidney Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms, Male 2Uterine Cervical Neoplasms 1Urologic Neoplasms 1Triple Negative Breast Neoplasms 1Thrombocytosis 1Soft Tissue Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pheochromocytoma 1Pharyngeal Neoplasms 1

Interventions

tucatinib 1temsirolimus 1pembrolizumab 1niraparib 1lenvatinib 1atezolizumab 1Valproic Acid 1Trastuzumab 1Tissue Banks 1Sirolimus 1Immunoglobulin G 1Fulvestrant 1Doxycycline 1Disulfides 1Cetuximab 1Capecitabine 1Blood Specimen Collection 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urologic Neoplasms × Sirolimus × Breast × Clear all
NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡